OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Files An 8-K Other Events
Item 9.01 Other Events.
On January 7, 2019, in advance of a public webcast presentation at the J.P. Morgan Healthcare Conference on January 9, 2019, Oxford Immunotec Global PLC (the “Company”) released an investor presentation (the “Investor Presentation”). A copy of the Investor Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Investor Presentation is accessible via a link posted on the Investors, Events & Presentations section of the Company’s website: www.oxfordimmunotec.com.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Oxford Immunotec Global PLC Exhibit
…
To view the full exhibit click here
About OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD)
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient’s cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA.
